Strategies for Reducing Bispecific Therapy Toxicities

EP: 1.Bispecific Antibodies in DLBCL: Therapeutic Potential

EP: 2.Efficacy Insights on Bispecific Antibodies in DLBCL

EP: 3.Bispecific Antibodies in DLBCL Trials

EP: 4.Bispecific Antibodies in DLBCL: Patient Response

EP: 5.Future Insights on Bispecific Therapies

EP: 6.Overcoming DLBCL Treatment Hurdles

EP: 7.Patient Education and Monitoring in DLBCL Treatment

EP: 8.Implementing Bispecific Treatments

EP: 9.Bispecific Toxicity Management in DLBCL Care

EP: 10.Multidisciplinary Bispecific Care

EP: 11.Pharmacists: Bispecifics and Operational Role

Now Viewing

EP: 12.Strategies for Reducing Bispecific Therapy Toxicities

EP: 13.Unmet Needs in Bispecific Therapy Access

EP: 14.Implementing Bispecific Antibodies in Lymphoma Care

This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.

In this segment, Mahmoudjafari discusses the development and execution of innovative protocols to reduce treatment-related toxicities in patients receiving bispecific antibodies. Ali shares insights into managing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome, emphasizing the evolving understanding and tips gathered over time. Strategies include prophylactic tocilizumab, patients taking home dexamethasone, maintaining hydration, and adjusting intravenous infusion rates. The conversation explores potential changes in dosing frequency for myeloma bispecifics and addresses the balance between therapeutic efficacy and patient tolerability. The speakers emphasize the importance of education, shared decision-making, and ongoing learning in optimizing bispecific antibody treatments for patients with lymphomas.

This summary was AI-generated and reviewed by Pharmacy Times^® editorial staff.